AI Advocate Ari to Support Families Affected by Angelman Syndrome

The Angelman Syndrome Foundation (ASF) is taking a bold step towards improving the lives of families affected by this rare neurodevelopmental disorder. In collaboration with startup Citizen Health, ASF will introduce Ari, an artificial intelligence (AI) advocate specifically designed for rare disease communities. This initiative aims to provide much-needed support and resources to families navigating the challenges of Angelman syndrome.

Angelman syndrome affects approximately one in 15,000 people and is characterized by severe developmental delays, speech impairment, and frequent seizures. The journey for affected families can be overwhelming, both emotionally and logistically. Amanda Moore, CEO of the Angelman Syndrome Foundation, emphasizes the importance of this partnership: "Our mission has always been to make your journey easier. We want to help you day-to-day because the diagnosis is already extremely hard."

Empowering Families with Technology

ASF families will have their first opportunity to access Ari at the 2026 ASF Family Conference in Denver, scheduled from July 30 to August 1. Following the conference, a phased rollout will begin, starting with families in the United States and gradually expanding to ASF’s global community.

Ari is designed to assist families by aggregating medical records, coordinating care, and providing real-time support. For parents like Amanda Moore, who has a son diagnosed with Angelman syndrome, this tool represents a significant relief. "As a mom, I know how much of this work falls on parents, and how little technology has ever helped with it," she says. "Ari takes that load off."

The AI advocate is part of Citizen Health's broader mission to empower patients and families dealing with rare and complex conditions. Launched in late 2023, the platform leverages advanced machine learning to provide personalized support and streamline healthcare management.

The Bigger Picture

The introduction of Ari also highlights a growing trend in healthcare: the integration of AI to improve patient engagement and outcomes. This partnership is not just about providing immediate support; it's about laying the groundwork for more comprehensive care and research.

The Angelman Syndrome Foundation has been at the forefront of research, investing over $18 million in studies at universities and medical centers worldwide. This early investment has unlocked more than $200 million in additional funding, contributing to the development of several therapeutic approaches currently in clinical trials.

As investigational therapies for Angelman syndrome become available, the value of organized, real-world data increases. Ari can play a crucial role in collecting and analyzing this data, potentially accelerating research and improving treatment options. "The more we understand about how these therapies work in the real world, the better we can tailor them to individual needs," explains Moore.

This initiative aligns with broader efforts in healthcare to leverage technology for patient empowerment. For example, CVS has been working on simplifying the patient experience through various digital tools and services, recognizing that technology can significantly enhance care coordination and patient satisfaction.

The partnership between ASF and Citizen Health represents a significant step forward in rare disease management. By combining the expertise of a leading research foundation with cutting-edge AI technology, this collaboration aims to make a tangible difference in the lives of affected families. As the rollout progresses, the impact of Ari will be closely monitored, with the potential for expansion to other rare disease communities.

In a world where healthcare can often feel impersonal and overwhelming, initiatives like Ari offer a glimmer of hope and practical support. For families dealing with Angelman syndrome, this AI advocate is not just a tool; it's a lifeline.